Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. (TTNP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TTNP · as of Sep 30, 2025
Ownership Breakdown
17
Institutional Holders
▼ 3 vs Q2
$107,104
Total Inst. Value
▼ $51,172 vs Q2
1.33M
Shares Outstanding
freeFloat 61.91%
22,362
13F Shares Held
▼ 15,324 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TTNP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
DRW SECURITIES, LLC biological products, (no diagnostic substances) | 21.3K | 2.00% | 2.00% | $101.87M | Nov 14, 2025 | NEW |
UBS GROUP AG biological products, (no diagnostic substances) | 480 | 4.51% | 4.51% | $2.30M | Nov 13, 2025 | ▼ 2.9K |
TOWER RESEARCH CAPITAL LLC (TRC) biological products, (no diagnostic substances) | 469 | 4.40% | 4.40% | $2.25M | Nov 14, 2025 | NEW |
CORECAP ADVISORS, LLC biological products, (no diagnostic substances) | 88 | 0.83% | 0.83% | $422,000 | Oct 22, 2025 | — held |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 19 | 0.18% | 0.18% | $91,000 | Feb 3, 2026 | ▲ 1 |
GROUP ONE TRADING, L.P. biological products, (no diagnostic substances) | 12 | 0.11% | 0.11% | $58,000 | Nov 12, 2025 | — held |
ADVISOR GROUP HOLDINGS, INC. biological products, (no diagnostic substances) | 10 | 0.09% | 0.09% | $35,000 | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 6 | 0.06% | 0.06% | $29,000 | Nov 12, 2025 | — held |
MORGAN STANLEY biological products, (no diagnostic substances) | 2 | 0.02% | 0.02% | $10,000 | May 27, 2026 | — held |
GLOBAL WEALTH STRATEGIES & ASSOCIATES biological products, (no diagnostic substances) | 2 | 0.02% | 0.02% | $10,000 | Oct 2, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
1
Increased
+1 shares2
New Positions
first time holders1
Decreased
−2.9K shares5
Sold Out
fully exitedNet shares change (top 50)
2.9K
+1 / −2.9K
Net new holders
-3
2 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TTNP insider trading · insider activity
Source: SEC Form 4
5
Buy transactions
1
Sell transactions
5.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Ben-Tzvi Avraham director | Oct 1, 2025 | D-Return | 3,313 | — | — | 0 | Form 4 ↗ |
Ben-Tzvi Avraham director | Oct 1, 2025 | D-Return | 5,000 | — | — | 0 | Form 4 ↗ |
Choong Choon Hau 10 percent owner | Mar 18, 2024 | C-Conversion | 54,132 | — | — | 3.80M | Form 4 ↗ |
Choong Choon Hau 10 percent owner | Mar 18, 2024 | C-Conversion | 0 | $9.32 | $0 | 0 | Form 4 ↗ |
NATAN DAVID director | Oct 25, 2023 | Award | 16,250 | — | — | 66.3K | Form 4 ↗ |
McMurdo Matthew Charles director | Oct 25, 2023 | Award | 16,250 | — | — | 66.3K | Form 4 ↗ |
Greenberg Eric Howard director | Oct 25, 2023 | Award | 16,250 | — | — | 66.3K | Form 4 ↗ |
Beebe Katherine President and COO | Oct 25, 2023 | Award | 16,250 | — | — | 66.3K | Form 4 ↗ |
Ben-Tzvi Avraham director | Oct 25, 2023 | Award | 16,250 | — | — | 66.3K | Form 4 ↗ |
Greenberg Eric Howard director | Jun 29, 2023 | Award | 100,000 | $1.31 | $131.0K | 100.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Titan Pharmaceuticals, Inc. (TTNP) is primarily owned by institutional investors, who hold approximately 1.7% of total shares outstanding. Company insiders own approximately 38.09%, while retail and public investors account for the remaining 60.23%.
The largest institutional shareholder of Titan Pharmaceuticals, Inc. is DRW SECURITIES, LLC, holding approximately 21,267 shares — equal to 2.00% of outstanding shares — as of September 30, 2025.
A total of 17 institutional investors currently hold TTNP stock, with a combined institutional value of approximately $107,104 as of the most recent 13F filing period.
Frequently asked questions
TTNP ownershipTitan Pharmaceuticals, Inc. (TTNP) is primarily owned by institutional investors, who hold approximately 1.7% of shares. The largest shareholder is DRW SECURITIES, LLC with a 2.00% stake. Company insiders hold 38.09%. Data sourced from SEC Form 13F as of September 30, 2025.